Antimicrobial susceptibilities and clinical sources of Facklamia species

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 8, 2000, Pages 2130-2132

  LaClaire, L ^a   Facklam, R ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ARTICLE; CEREBROSPINAL FLUID; DILUTION; FACKLAMIA; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BLOOD; BONE AND BONES; CHILD; FEMALE; GRAM-POSITIVE COCCI; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; URINARY BLADDER;

EID: 0033942828     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.8.2130-2132.2000     Document Type: Article

References (15)

1. Alcaide, F., J. Linares, R. Pallares, J. Carratala, M. A. Benitez, F. Gudiol, and R. Martin. 1995. In vitro activities of 22 β-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood. Antimicrob. Agents Chemother. 39:2243-2247.
2. Collins, M. D., E. Falsen, J. Lemozy, E. Akervall, B. Sjoden, and P. A. Lawson. 1997. Phenotypic and phylogenetic characterization of some Globicatella-like organisms from human sources: description of Facklamia hominis gen. nov., sp. nov. Int. J. Syst. Bacteriol. 43:880-882.
3. Collins, M. D., R. A. Hutson, E. Falsen, and B. Sjoden. 1999. Facklamia sourekii sp. nov., isolated from human sources. Int. J. Syst. Bacteriol. 49:635-638.
4. Collins, M. D., R. A. Hutson, E. Falsen, and B. Sjoden. 1999. Facklamia tabacinasalis sp. nov., from powdered tobacco. Int. J. Syst. Bacteriol. 49: 1247-1250.
5. Collins, M. D., P. A. Lawson, R. Monasterio, E. Falsen, B. Sjoden, and R. R. Facklam. 1998. Facklamia ignava sp. nov., isolated from clinical specimens. J. Clin. Microbiol. 36:2145-2148.
6. De Azavedo, J. C. S., L. Trpeski, S. Pong-Porter, S. Matsumura, The Canadian Bacterial Surveillance Network, and D. E. Low. 1999. In vitro activities of fluoroquinolones against antibiotic-resistant blood culture isolates of viridans group streptococci across Canada. Antimicrob. Agents Chemother. 43:2299-2301.
7. Doern, G. V. M., J. Ferraro, A. B. Brueggemann, and K. L. Ruoff. 1996. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob. Agents Chemother. 40:891-894.
8. Facklam, R., and J. A. Elliott. 1995. Identification, classification, and clinical relevance of catalase-negative, gram-positive cocci, excluding the streptococci and enterococci. Clin. Microbiol. Rev. 8:479-495.
9. Frandsen, E. V. G., V. Pedrazzoli, and M. Kilian. 1991. Ecology of viridans streptococci in the oral cavity and pharynx. Oral Microbiol. Immunol. 6:129-133.
10. LaClaire, L., and R. Facklam. 2000. Comparison of three commercial rapid identification systems for the unusual gram-positive cocci Dolosigranulum pigrum, Ignavigranum ruoffiae, and Facklamia species. J. Clin. Microbiol. 38:2037-2042.
11. Lawson, P. A., M. D. Collins, E. Falsen, B. Sjoden, and R. R. Facklam. 1999. Facklamia languida sp. nov., isolated from clinical human specimens. J. Clin. Microbiol. 37:1161-1164.
12. Miller, P. H., R. R. Facklam, and J. M. Miller. 1996. Atmospheric growth requirements for Alloiococcus species and related gram-positive cocci. J. Clin. Microbiol. 34:1027-1028.
13. National Committee for Clinical Laboratory Standards. 1998. Performance standards for antimicrobial susceptibility testing, vol. 19, M100-S9. National Committee for Clinical Laboratory Standards, Wayne, Pa.
14. Pottumarthy, S., and A. J. Morris. 1998. Detection of decreased penicillin susceptibility in viridans group of streptococci. Pathology 30:188-191.
15. Teng, L. J., P. R. Hsueh, Y. C. Chen, S. W. Ho, and K. T. Luh. 1998. Antimicrobial susceptibility of viridans group streptococci in Taiwan with an emphasis on the high rates of resistance to penicillin and macrolides in Streptococcus oralis. J. Antimicrob. Chemother. 41:621-627.